Hamid, O., Puzanov, I., Dummer, R., Schachter, J., Daud, A., Schadendorf, D., … Ribas, A. (2016). Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology, 27, vi379. https://doi.org/10.1093/annonc/mdw379.02

Hamid, O., I. Puzanov, R. Dummer, J. Schachter, A. Daud, D. Schadendorf, C. Blank, et al. “Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.” Annals of Oncology 27 (October 1, 2016): vi379. https://doi.org/10.1093/annonc/mdw379.02.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology. 2016 Oct 1;27:vi379.

Hamid, O., et al. “Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.” Annals of Oncology, vol. 27, Oct. 2016, p. vi379. Scopus, doi:10.1093/annonc/mdw379.02.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama A, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus SW, Ibrahim N, Ribas A. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology. 2016 Oct 1;27:vi379.